--- title: "Forte Biosciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Forte Biosciences, Inc. - FBRX" type: "News" locale: "en" url: "https://longbridge.com/en/news/295559644.md" description: "Kahn Swick & Foti, LLC is investigating the proposed sale of Forte Biosciences (FBRX) to argenx SE. The transaction offers shareholders $77.00 per share in cash. The law firm is assessing whether this price and the deal process are adequate or if they undervalue the company. Shareholders concerned about potential undervaluation or wishing to discuss legal rights are encouraged to contact Managing Partner Lewis S. Kahn." datetime: "2026-08-11T16:08:46.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/295559644.md) - [en](https://longbridge.com/en/news/295559644.md) - [zh-HK](https://longbridge.com/zh-HK/news/295559644.md) generator: "portal-rs" --- # Forte Biosciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Forte Biosciences, Inc. - FBRX Forte Biosciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Forte Biosciences, Inc. - FBRX Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Forte Biosciences, Inc. (NasdaqCM: FBRX) to argenx SE (NasdaqGS: ARGX). Under the terms of the proposed transaction, shareholders of Forte will receive $77.00 in cash for each share of Forte that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company. If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn (lewis.kahn@ksfcounsel.com) toll free at any time at (833) 538-3612, or visit https://www.ksfcounsel.com/cases/nasdaqcm-fbrx/ to learn more. ***Please note that the transaction is structured as a tender offer, such that time may be of the essence.*** To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com. CONNECT WITH US: Facebook || Instagram || YouTube || TikTok || LinkedIn Kahn Swick & Foti, LLC Lewis S. Kahn, Managing Partner lewis.kahn@ksfcounsel.com (833) 538-3612 1100 Poydras St., Suite 960 New Orleans, LA 70163 View source version on businesswire.com: https://www.businesswire.com/news/home/20260811200449/en/ ### Related Stocks - [FBRX.US](https://longbridge.com/en/quote/FBRX.US.md) - [ARGX.US](https://longbridge.com/en/quote/ARGX.US.md) - [34962G208.US](https://longbridge.com/en/quote/34962G208.US.md) ## Related News & Research - [Jefferies Sticks to Its Buy Rating for Argenx Se (ARGX)](https://longbridge.com/en/news/299068542.md) - [Forte Biosciences seeks Nasdaq delisting, plans to end SEC reporting after merger closes](https://longbridge.com/en/news/297228231.md) - [Squarepoint Ops LLC Takes Position in EverQuote, Inc. $EVER](https://longbridge.com/en/news/298886977.md) - [argenx completes acquisition of Forte Biosciences for $77 per share](https://longbridge.com/en/news/297189309.md) - [Concurrent Investment Advisors LLC Sells 8,348 Shares of Fabrinet $FN](https://longbridge.com/en/news/298554832.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**